InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by Rodino-Klapac Louise, Directeur Scientifique. Officer active across 1 company, notably Sarepta Therapeutics, Inc.. Cumulatively, 6 reports have been published. Split: 2 buys · 0 sell. Total volume traded: €533k. History available since 16 November 2021. The latest transaction was filed on 4 March 2022 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Declarations6 total
1,216 shares@ US$79.200.0039% mcap13.2% of flowCommon StockSEC:0001209191-22-017343:0
572 shares@ US$75.050.0017% mcap5.8% of flowCommon StockSEC:0001209191-22-014409:0
3,780 shares@ US$79.330.012% mcap40.5% of flowCommon StockSEC:0001209191-21-066948:0
Ideal exit: 21 Aug 2022 (T+270)
3,780 shares@ US$79.33100.0% of flowCommon StockSEC:0001209191-21-066948
Ideal exit: 21 Aug 2022 (T+270)
40,000 shares0Common StockSEC:0001209191-21-065314:0
40,000 shares0Common StockSEC:0001209191-21-065314
6 of 6 declarations
About Rodino-Klapac Louise
Louise Rodino-Klapac is the Chief Scientific Officer and Head of R&D at Sarepta Therapeutics, Inc. She oversees the company's research and development activities, playing a key role in innovation and the development of new products. Her scientific expertise is essential to the company's mission.
